Company intelligence / Profile preview
Shanghai Runshi Pharmaceutical Technology Co., Ltd.
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has multiple products in clinical development, with Simmitinib (targeting FGFRs, M-CSF, VEGFR2) in Phase 3 for Metastatic Esophageal Squamous Cell Carcinoma, Enlonstobart (targeting PD-1) in Phase 2 for Advanced Malignant Solid Neoplasm, and Trastuzumab envedotin (targeting HER2 and Tubulin) for Metastatic Gastroesophageal Junction Adenocarcinoma
- Therapeutic areas
- GastroenterologyEndocrinologyDermatologyHematologyOncologyNeurology
- Modalities
- Small molecule drugsAntibody drug conjugate (ADC)Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences
Beyond the preview
Go deeper on Shanghai Runshi Pharmaceutical Technology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Runshi Pharmaceutical Technology Co., Ltd..